MANN + HUMMEL (UK) LIMITED

Comprehensive Financial Health Assessment: MANN + HUMMEL (UK) LIMITED

1. Financial Health Score: B+

Explanation: Based on the available vital signs, the patient exhibits a robust constitution and excellent compliance health. The substantial share capital of £4.5 million acts as a strong skeletal structure, indicating a well-capitalized entity capable of withstanding economic shocks. However, a definitive 'A' grade cannot be awarded without viewing the complete blood work—specifically, the detailed profit and loss metrics, cash flow statements, and current asset/liability ratios, which are not present in the current dataset.

2. Key Vital Signs

• Corporate Age & Status (Longevity): Incorporated in 1996, this is a mature entity nearing 30 years of active trading. In medical terms, this indicates a patient with a long, stable history of survival, far removed from the high-mortality infancy stage of businesses.
• Compliance & Filing Health (Immune System): The company’s regulatory immune system is functioning perfectly. Accounts are filed up to date (last made up to 31 Dec 2025, next due Sept 2027) with no overdue flags. This indicates strong administrative health and a low risk of regulatory infection (fines or penalties).
• Share Capital (Bone Density): With a share capital of £4,500,001, the company possesses excellent financial bone density. This is not a shell or micro-entity; it is a significantly capitalized business, providing a thick cushion against operational liabilities.
• Governance & Board Composition (Nervous System): The board features a mix of UK, Irish, and German directors, including specific roles like "Director Automotive Aftermarket UK And Ireland" and "Operations Director." This specialized, international nervous system strongly suggests the company operates as a strategic subsidiary of the global MANN+HUMMEL Group, benefiting from overarching corporate governance and support.
• PSC (Genetic Lineage): The "Persons with significant control statement" indicates that control is likely exercised by a parent undertaking rather than individual shareholders, confirming its status as a subsidiary within a larger corporate family tree.

3. Diagnosis

Structurally Sound, Awaiting Full Blood Work

The financial data reveals a business that is in robust structural health. The absence of overdue filings, the substantial share capital, and the deep connection to a global manufacturing parent (MANN+HUMMEL is a renowned global filtration expert) suggest this UK entity is not a risky standalone venture, but rather a well-supported limb of a larger corporate body.

However, we are currently missing the critical lab results—namely the current ratios, cash flow health, and retained earnings. Without the Net Current Assets, P&L Reserve, or specific turnover figures, we cannot measure the company's day-to-day metabolic rate (liquidity) or its recent profitability. The healthy vital signs we can see strongly suggest the underlying business health is good, but the absence of these specific financial metrics means we must treat the patient as stable but requiring further observation.

4. Recommendations

To achieve a complete picture of financial wellness and move toward an 'A' health rating, the following actions are recommended:

• Request the Full Financial Blood Panel: Obtain the full filed accounts to analyze working capital (Current Assets minus Current Liabilities) and retained profits. This will reveal if the company is generating healthy cash flow or relying on parental life support (inter-company loans).
• Monitor Inter-Company Balances: Given the clear international parentage, it is common for subsidiaries to carry large inter-company debts. Ensure these are structured favorably and do not represent a hidden financial illness that could restrict UK liquidity.
• Maintain Compliance Vigilance: Continue the excellent track record of timely filings. A healthy regulatory immune system prevents unnecessary stress and preserves the company's spotless public record.